Exploring regulatory flexibility to create novel incentives to optimize drug discovery

Area of Science:

• Pharmaceutical sciences
• Health policy
• Innovation studies

Background:

• Drug development faces declining efficiency, hindering access to pioneering medicines for critical health needs.
• Multi-sectoral collaborations are vital for innovation but current incentives primarily benefit drug manufacturers, not collaborative efforts.
• Existing pharmaceutical regulations offer limited stimulation for diverse stakeholder engagement in early drug development.

Purpose of the Study:

• To explore the potential of pharmaceutical regulations to foster collaborative innovation in early drug development.
• To identify novel incentive mechanisms within regulations that encourage diverse public and private actors to engage in knowledge exchange.
• To address the challenge of diminishing efficiency in developing pioneering drugs.

Main Methods:

• Mini-review of existing literature and pharmaceutical regulatory frameworks.
• Analysis of current incentive structures in drug development.
• Exploration of potential regulatory modifications to encourage multi-sectoral collaboration.

Main Results:

• Current incentives in drug development are narrowly focused on manufacturers, failing to stimulate broader collaborative innovation.
• Pharmaceutical regulations possess untapped potential for creating new incentives.
• Novel regulatory approaches can encourage diverse public and private entities to participate in early-stage drug development.

Conclusions:

• Reforming pharmaceutical regulations can create powerful incentives for multi-sectoral collaboration.
• Encouraging diverse stakeholder engagement through regulatory adjustments is key to enhancing early drug development innovation.
• Leveraging regulatory frameworks offers a promising strategy to counteract declining drug development efficiency.